• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

    11.98 -0.11 (-0.91%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,537,810
    Open 11.92
    Bid (Size) 11.60 (1)
    Ask (Size) 12.25 (12)
    Prev. Close 12.09
    Today's Range 11.83 - 12.04
    52wk Range 3.555 - 12.52
    Shares Outstanding 56,434,219
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
    From Kahn Swick & Foti, LLC
    Via Business Wire
    SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire

    Performance

    YTD
    +33.6%
    +33.6%
    1 Month
    +64.8%
    +64.8%
    3 Month
    +92.0%
    +92.0%
    6 Month
    +196.5%
    +196.5%
    1 Year
    +3.6%
    +3.6%

    More News

    Read More
    BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play
    Via Stocktwits
    BioCryst To Acquire Astria Therapeutics In $700M Deal
    Via Stocktwits
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    This Verisk Analytics Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
    Via Benzinga
    SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS and RYN on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    Dow Jumps Over 300 Points; Citigroup Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
    Via Benzinga
    Which stocks are gapping on Tuesday?
    Via Chartmill
    Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Which stocks are moving before the opening bell on Tuesday?
    Via Chartmill
    ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference
    From Astria Therapeutics, Inc.
    Via Business Wire
    Astria Therapeutics Inc (NASDAQ:ATXS) Reports Narrower-Than-Expected Q2 2025 Loss and Strong Cash Runway
    Via Chartmill

    Frequently Asked Questions

    Is Astria Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Astria Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Astria Therapeutics, Inc. - Common Stock trade on?
    Astria Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Astria Therapeutics, Inc. - Common Stock?
    The ticker symbol for Astria Therapeutics, Inc. - Common Stock is ATXS on the Nasdaq Stock Market
    What is the current price of Astria Therapeutics, Inc. - Common Stock?
    The current price of Astria Therapeutics, Inc. - Common Stock is 11.98
    When was Astria Therapeutics, Inc. - Common Stock last traded?
    The last trade of Astria Therapeutics, Inc. - Common Stock was at 10/17/25 04:00 PM ET
    What is the market capitalization of Astria Therapeutics, Inc. - Common Stock?
    The market capitalization of Astria Therapeutics, Inc. - Common Stock is 676.08M
    How many shares of Astria Therapeutics, Inc. - Common Stock are outstanding?
    Astria Therapeutics, Inc. - Common Stock has 676M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.